omeprazole and tacrolimus

omeprazole has been researched along with tacrolimus in 30 studies

Research

Studies (30)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (3.33)	18.2507
2000's	17 (56.67)	29.6817
2010's	7 (23.33)	24.3611
2020's	5 (16.67)	2.80

Authors

Authors	Studies
Li, Y; Li, YH; Wang, YH; Yang, L; Yang, SL	1
Lombardo, F; Obach, RS; Waters, NJ	1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV	1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV	1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF	1
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M	1
Goto, H; Hamajima, E; Hoshino, H; Ozawa, T; Sugiyama, S; Tsukamoto, Y	1
Lorf, T; Ramadori, G; Ringe, B; Schwörer, H	1
Lorf, T; Ramadori, G; Ringe, B; Schwrer, H	1
Fukao, K; Homma, M; Itagaki, F; Kohda, Y; Yuzawa, K	2
Bowrey, DJ; Jurewicz, WA; Logan, AJ; Morris-Stiff, GJ	1
Inui, K; Ito, N; Motohashi, H; Ogawa, O; Okuda, M; Takahashi, K; Yamamoto, S; Yonezawa, A	1
Homma, M; Itagaki, F; Kohda, Y; Naito, S; Nishimura, M; Ohkohchi, N; Ueda, N; Yuzawa, K	1
Kunicki, PK; Sobieszczańska-Małek, M	1
Lemahieu, WP; Maes, BD; Vanrenterghem, Y; Verbeke, K	1
Habuchi, T; Kagaya, H; Miura, M; Sagae, Y; Satoh, S; Suzuki, T; Tada, H	1
Alarcón, MC; Burgos, FJ; Marcén, R; Navarro, M; Ocaña, J; Orea, OE; Ortuño, J; Pascual, J; Villafruela, JJ	1
Debray, D; Furlan, V; Loriot, MA; Moreau, C; Taburet, AM	1
Fukuhara, Y; Inui, K; Ito, N; Katsura, T; Ogawa, O; Takahashi, K; Takahashi, T; Yamamoto, S; Yano, I	1
Egawa, H; Hosohata, K; Inui, K; Kaido, T; Katsura, T; Masuda, S; Ogura, Y; Oike, F; Takada, Y; Uemoto, S	1
Baudouin, V; Deschênes, G; Fakhoury, M; Jacqz-Aigrain, E; Maisin, A; Storme, T; Zhao, W	1
Aliño, SF; Bea, S; Bosó, V; Galiana, M; Hernández, J; Herrero, MJ; Marqués, MR; Marrero, P; Poveda, JL; Sánchez-Plumed, J	1
Bossolani, MV; de Oliveira, HB; Faria, PN; Ferreira Filho, SR; Peloso, LJ	1
Dorji, C; Na-Bangchang, K; Robin, FA	1
Li, Y; Liu, Y; Sun, Z	1
Idasiak-Piechocka, I; Miedziaszczyk, M	1

Reviews

3 review(s) available for omeprazole and tacrolimus

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators. European journal of medicinal chemistry, 2022, Jul-05, Volume: 237 Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells	2022
Safety analysis of co-administering tacrolimus and omeprazole in renal transplant recipients - A review. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2023, Volume: 166 Topics: Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Humans; Kidney; Kidney Transplantation; Omeprazole; Tacrolimus	2023

Trials

4 trial(s) available for omeprazole and tacrolimus

Article	Year
Upper gastrointestinal complications after renal transplantation: a 3-yr sequential study. Clinical transplantation, 2002, Volume: 16, Issue:3 Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Child; Child, Preschool; Cyclosporine; Enzyme Inhibitors; Female; Gastrointestinal Diseases; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Omeprazole; Prospective Studies; Ranitidine; Tacrolimus; Treatment Outcome	2002
Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations. The Journal of pharmacy and pharmacology, 2004, Volume: 56, Issue:8 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cross-Over Studies; Cytochrome P-450 CYP2C19; Drug Interactions; Female; Genotype; Humans; Immunosuppressive Agents; Lansoprazole; Male; Metabolic Clearance Rate; Middle Aged; Mixed Function Oxygenases; Omeprazole; Rabeprazole; Tacrolimus	2004
Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. Xenobiotica; the fate of foreign compounds in biological systems, 2005, Volume: 35, Issue:5 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cytochrome P-450 CYP2C19; Dexlansoprazole; Humans; Immunosuppressive Agents; Kidney Transplantation; Kinetics; Lansoprazole; Mixed Function Oxygenases; Models, Molecular; Molecular Structure; Omeprazole; Rabeprazole; Stereoisomerism; Substrate Specificity; Tacrolimus	2005
Interaction between omeprazole and tacrolimus in renal allograft recipients: a clinical-analytical study. Transplantation proceedings, 2005, Volume: 37, Issue:9 Topics: Anti-Ulcer Agents; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Kidney Transplantation; Omeprazole; Postoperative Complications; Tacrolimus	2005

Other Studies

23 other study(ies) available for omeprazole and tacrolimus

Article	Year
Modeling K(m) values using electrotopological state: substrates for cytochrome P450 3A4-mediated metabolism. Bioorganic & medicinal chemistry letters, 2005, Sep-15, Volume: 15, Issue:18 Topics: Computational Biology; Cyclohexanols; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Molecular Structure; Principal Component Analysis; Pyrrolizidine Alkaloids; Quantitative Structure-Activity Relationship; Reproducibility of Results; Substrate Specificity; Venlafaxine Hydrochloride	2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7 Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding	2008
Physicochemical determinants of human renal clearance. Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15 Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight	2009
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. Journal of medicinal chemistry, 2010, Feb-11, Volume: 53, Issue:3 Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations	2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests	2013
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology. Disease models & mechanisms, 2023, 03-01, Volume: 16, Issue:3 Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries	2023
Effects of FK506, an immunosuppressive agent, on genesis of water-immersion stress-induced gastric lesions in rats. Digestive diseases and sciences, 1994, Volume: 39, Issue:4 Topics: Animals; Famotidine; Gastric Mucosa; Immersion; Leukotrienes; Male; Omeprazole; Peroxidase; Polyethylene Glycols; Prostaglandins; Rats; Rats, Wistar; Stomach Ulcer; Stress, Physiological; Superoxide Dismutase; Tacrolimus; Xanthine Oxidase	1994
The effect of pantoprazole on tacrolimus and cyclosporin A blood concentration in transplant recipients. European journal of clinical pharmacology, 2000, Volume: 56, Issue:5 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Benzimidazoles; Cyclosporine; Enzyme Inhibitors; Enzyme Multiplied Immunoassay Technique; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Omeprazole; Organ Transplantation; Pantoprazole; Sulfoxides; Tacrolimus	2000
Pantoprazole and cyclosporine or tacrolimus. Alimentary pharmacology & therapeutics, 2001, Volume: 15, Issue:4 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Cyclosporine; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Humans; Immunosuppressive Agents; Liver; Mixed Function Oxygenases; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Sulfoxides; Tacrolimus	2001
Effects of lansoprazole and rabeprazole on tacrolimus blood concentration: case of a renal transplant recipient with CYP2C19 gene mutation. Transplantation, 2002, Jan-27, Volume: 73, Issue:2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Exons; Female; Humans; Immunosuppressive Agents; Lansoprazole; Middle Aged; Mixed Function Oxygenases; Mutation; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Tacrolimus	2002
Drug interaction of tacrolimus and proton pump inhibitors in renal transplant recipients with CYP2C19 gene mutation. Transplantation proceedings, 2002, Volume: 34, Issue:7 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cytochrome P-450 CYP2C19; Drug Interactions; Famotidine; Female; Humans; Immunosuppressive Agents; Kidney Transplantation; Lansoprazole; Male; Middle Aged; Mixed Function Oxygenases; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Tacrolimus	2002
Lansoprazole-tacrolimus interaction in Japanese transplant recipient with CYP2C19 polymorphism. The Annals of pharmacotherapy, 2004, Volume: 38, Issue:5 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Drug Synergism; Humans; Immunosuppressive Agents; Kidney Transplantation; Lansoprazole; Male; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic; Tacrolimus	2004
Pharmacokinetic interaction between tacrolimus and clarithromycin in a heart transplant patient. Therapeutic drug monitoring, 2005, Volume: 27, Issue:1 Topics: Area Under Curve; Azathioprine; Clarithromycin; Drug Administration Schedule; Drug Interactions; Duodenitis; Half-Life; Heart Transplantation; Helicobacter Infections; Humans; Male; Middle Aged; Omeprazole; Tacrolimus	2005
Impact of gastric acid suppressants on cytochrome P450 3A4 and P-glycoprotein: consequences for FK506 assimilation. Kidney international, 2005, Volume: 67, Issue:3 Topics: Adult; Aged; Anti-Ulcer Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cimetidine; Cohort Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Gastric Acid; Humans; Kidney Transplantation; Male; Middle Aged; Omeprazole; Tacrolimus	2005
Interaction between tacrolimus and omeprazole in a pediatric liver transplant recipient. Transplantation, 2006, Feb-15, Volume: 81, Issue:3 Topics: Adolescent; Anti-Ulcer Agents; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Humans; Immunosuppressive Agents; Liver Transplantation; Male; Omeprazole; Tacrolimus	2006
Distinct effects of omeprazole and rabeprazole on the tacrolimus blood concentration in a kidney transplant recipient. Drug metabolism and pharmacokinetics, 2007, Volume: 22, Issue:6 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Monitoring; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole; Tacrolimus	2007
Impact of intestinal CYP2C19 genotypes on the interaction between tacrolimus and omeprazole, but not lansoprazole, in adult living-donor liver transplant patients. Drug metabolism and disposition: the biological fate of chemicals, 2009, Volume: 37, Issue:4 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Drug Interactions; Female; Genotype; Humans; Immunosuppressive Agents; Lansoprazole; Liver Transplantation; Living Donors; Male; Middle Aged; Omeprazole; Tacrolimus	2009
Pharmacogenetic determinant of the drug interaction between tacrolimus and omeprazole. Therapeutic drug monitoring, 2012, Volume: 34, Issue:6 Topics: Adolescent; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biotransformation; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Drug Interactions; Humans; Immunosuppressive Agents; Kidney Transplantation; Omeprazole; Tacrolimus; Treatment Outcome	2012
Increased hospital stay and allograft dysfunction in renal transplant recipients with Cyp2c19 AA variant in SNP rs4244285. Drug metabolism and disposition: the biological fate of chemicals, 2013, Volume: 41, Issue:2 Topics: Aryl Hydrocarbon Hydroxylases; Chi-Square Distribution; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Drug Monitoring; Enzyme Induction; Enzyme Inhibitors; Female; Genetic Predisposition to Disease; Humans; Immunosuppressive Agents; Kidney Transplantation; Length of Stay; Male; Middle Aged; Nod2 Signaling Adaptor Protein; Omeprazole; Pharmacogenetics; Phenotype; Polymorphism, Single Nucleotide; Postoperative Complications; Proton Pump Inhibitors; Substrate Specificity; Tacrolimus	2013
The serum concentration of tacrolimus after ingesting omeprazole: a pilot study. Transplantation, 2014, Sep-27, Volume: 98, Issue:6 Topics: Adult; Double-Blind Method; Drug Administration Schedule; Female; Humans; Immunoassay; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Omeprazole; Pilot Projects; Prevalence; Proton Pump Inhibitors; Tacrolimus	2014
Omeprazole-induced galactorrhea in kidney transplant patients-a case report. Journal of medical case reports, 2022, Mar-27, Volume: 16, Issue:1 Topics: Adult; Bhutan; Female; Galactorrhea; Humans; Kidney Transplantation; Omeprazole; Pregnancy; Tacrolimus	2022
Investigation of pharmacologic interactions between omeprazole and tacrolimus in a membranous nephropathy patient with CYP3A5 nonexpresser: a case report. Pharmacogenetics and genomics, 2022, 09-01, Volume: 32, Issue:7 Topics: Cytochrome P-450 CYP3A; Genotype; Glomerulonephritis, Membranous; Humans; Immunosuppressive Agents; Omeprazole; Polymorphism, Single Nucleotide; Tacrolimus	2022